Strong start to the week: A clear upward trend, especially between Monday and Wednesday, when the price rose from ~4.33 to ~4.63 USD.

The price seems to be in a positive momentum - could indicate that market participants are becoming more optimistic.

Analysts rate with price targets above current levels, which could be further upside potential.

Who of you is also invested? 🚀

$CV

#aktien
#investing
#capsoVision
#rendite
#wachstum
#börsennews
#smallcaps
#trading
#wochenrückblick
#finanzwissen
#anleger
#börsentalk
#investieren
#etfs
#börse

On August 27, CapsoVision $CV announced that CFO Kevin Lundquist is stepping down. Importantly, he will remain with the company as a consultant until the end of February 2026 - a clearly regulated transition.

🔎 What does this mean for the share?

• Such CFO changes often lead to uncertainty in the short term, sometimes with -1 to -3 % share price movement.
• In the long term, however, the effects are usually neutral - the decisive factor is that the business and the product pipeline remain intact.
• In the case of CapsoVision, the decisive catalysts continue to be the 510(k) approval of the Colon capsule (2026) and the planned AI modules.

👉 For me, this is more of a small interim announcementnot a game changer. The story remains exciting, as the market launch of the Colon capsule holds the real upside potential.

How do you see it? Do you react to CFO changes with sales - or do you remain relaxed and invested in such news? 💭

#CapsoVision
#MedTech
#SmallCapStocks
#GrowthStocks
#IPO2025
#FDAApproval
#InvestmentCommunity
#invest
#aktien

📈 New purchase - CapsoVision

I am with CapsoVision
$CV an innovative MedTech company that is setting new standards with its 360° capsule endoscopy. No external recorder required, full perspective - and already FDA-approved & in use in the USA.

💡 Why this investment?

• Technological advantage compared to traditional solutions (e.g. PillCam from Medtronic)
• Already cooperating with Pentax Medical
• Focus on early detection & diagnosticsa megatrend in the healthcare sector
• Low market capitalization (~180m USD) with a lot of upside potential

🚀 Vision:

If CapsoVision reaches USD 50-100m sales in the medium term, a multiple in the share price is possible. In the long term I see 10-25 USD+ per share as realistic - depending on market penetration and access to capital, of course.

I think: exciting small cap story with disruptive potential - What do you think?

👉 Do you know the company? How do you rate the opportunities & risks?

Please leave your opinion!

#aktien
#investieren
#MedTech
#CapsoVision
#SmallCap
#langfristig
#innovation
#getquin
#medizin
#medizintechnik
#pharma
#medical
#zukunft
$NOVO B (+0,5 %)
$PLTR (-0,28 %)
$AMD (-0,91 %)
$NOVN (+0,65 %)

Hey community 👋 do you already know CapsoVision Inc.a newly listed MedTech company with a focus on capsule endoscopy and AI-supported diagnostics?

The company is developing capsules that patients can swallow to examine the small intestine or, in future, the large intestine -> non-invasively.

This capsule is approved worldwide, wireless incl. 360° panorama.

IPO was completed on July 3, 2025.

Some figures:

Turnover (TTM) approx. USD 12 million

YoY growth +38 %

Gross margin 63 %

Loss (TTM) approx. USD -21 million

EV/Sales approx. 16×

Cash after IPO ~26m USD

Of course, this is not a dividend stock - high losses, high expectations, but also:

✅ Real product on the market

✅ Innovation with AI potential

✅ Good gross margin & sales growth

✅ Just went public → plenty of room for discovery

👉 I'm curious to see whether CapsoVision will become a success story à la "MedTech Hidden Champion" in 2-3 years - or whether it will remain an attempt.

What do you think?

$CV
#ipo
#medtech
#medizin
#health
#gesundheit
#aktie
#nasdaq
#medical
#gesund
#pharma
#international
#getquin
#deutschland
#österreich
#schweiz
#usa